The New England Journal of Medicine (NEJM) RSS feed -- Search Results in Gastroenterology. NEJM (https://www.nejm.org) is a weekly general medical journal that publishes new medical research findings, review articles, and editorial opinion on a wide variety of topics of importance to biomedical science and clinical practice. https://www.nejm.org/action/showPodcastsFeeds NEJM Group Sun, 14 Jun 2026 02:22:20 GMT 2026 NEJM Group en-us 1440 A 66-year-old man with a history of Crohn’s disease treated with long-term adalimumab presented with fever and swelling of both knees. Analysis of a biopsy sample of the left knee synovium showed an atypical T-cell infiltrate. https://www.nejm.org/doi/full/10.1056/NEJMicm2501877?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMicm2501877 Edward Robert Scheffer Cliff, Melita Kenealy 2026-06-13 Immunosuppression-Associated Peripheral T-Cell Lymphoma Neutralizing interleukin-10 autoantibodies were found in a subgroup of patients with inflammatory bowel disease and in no controls without IBD. Seropositivity was strongly associated with the IBD HLA-DRB1*01:03 risk allele. https://www.nejm.org/doi/full/10.1056/NEJMoa2513654?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2513654 Nima Gharahdaghi, Pai-Jui Yeh, Lourdes Ceron-Gutierrez, Helen Griffin, Hannah Gordon, Chamara Jayamanne, Alice Fracchia, Amanda Y. Chong, Alissa Walsh, Oliver Brain, Katherine Baker, Hannah Kockelbergh, Yang Luo, Martha Guevara Becerra, Katherine Vadakethala, Madeleine Coy, Ladan Kabiri, Martin Barnardo, Susanna Dunachie, Barbara Kronsteiner, Anna Adams, Darren Fowler, Qian Zhang, Laura Fachal, Carl A. Anderson, Rofaida Desoki, Marie Vibeke Vestergaard, Lone Larsen, Nicola J. Wyatt, Robert D. Lees, Robert J. Mulligan, Chaonan Dong, Mohmmed Tauseef Sharip, Siân E. Faustini, Adrian Shields, Julia Pakpoor, Bushra Naz, Alex Richter, Jack Satsangi, Christopher A. Lamb, Miles Parkes, Fiona Powrie, Alexander J. Mentzer, Aleksejs Sazonovs, Tine Jess, Paul Klenerman, Simon Travis, Sophie Hambleton, Rainer Doffinger, Holm H. Uhlig 2026-06-11 Interleukin-10 Autoantibodies and HLA-DRB1*01:03 in Inflammatory Bowel Disease The authors describe the scientific foundations of a study implicating autoantibodies against interleukin-10 in persons with inflammatory bowel disease. https://www.nejm.org/doi/full/10.1056/NEJMe2603635?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2603635 Paul Bastard, Jean-Laurent Casanova 2026-06-11 Science behind the Study: Autoantibodies against Cytokines — From Infection to Inflammation If the current cholera pandemic, which began in 1961, is ever to end, the world will need better cholera vaccines that are effective in young children and global access to safe water and adequate sanitation. https://www.nejm.org/doi/full/10.1056/NEJMp2600873?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMp2600873 Edward T. Ryan, Firdausi Qadri, Julia A. Lynch 2026-06-11 Global Cholera-Control Efforts — Progress and Remaining Challenges A 53-year-old man with Crohn’s disease and psoriasis presented with a 2-day history of headache, slurred speech, nausea, and vomiting. During the previous 2 weeks, he had had yellowing of the skin and eyes and dark urine. https://www.nejm.org/doi/full/10.1056/NEJMcps2506943?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMcps2506943 Brittany B. Bromfield, Nikroo Hashemi, Mark S. Redston, Katherine H. Walker, Bruce D. Levy 2026-06-04 The Unusual Suspects A study dissects the way in which fasting or a fasting-mimicking diet augments the effect of hormonal therapy in a mouse model of breast cancer. https://www.nejm.org/doi/full/10.1056/NEJMcibr2600647?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMcibr2600647 Nima Sharifi 2026-06-04 Fasting, Glucocorticoids, and Breast Cancer A 44-year-old man presented with a 4-year history of choking episodes while eating. Endoscopy revealed narrowing of the upper esophagus by a pulsating, cordlike structure in the posterior wall (shown in a video). https://www.nejm.org/doi/full/10.1056/NEJMicm2600585?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMicm2600585 Ishita Dubey, Neha Wadhwa 2026-06-04 Dysphagia Lusoria In a phase 3 trial, obexelimab led to a lower risk of disease flares than placebo among patients with IgG4-related disease. Glucocorticoid use was lower and the incidence of remission was higher with obexelimab than with placebo. https://www.nejm.org/doi/full/10.1056/NEJMoa2601337?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2601337 Emanuel Della-Torre, Matthew C. Baker, Wen Zhang, Cory A. Perugino, Guy Katz, Yoshiya Tanaka, Arezou Khosroshahi, Alexander Kleger, Nicolas Schleinitz, Fernando Martinez-Valle, Hendrik Schulze-Koops, Shingo Nakayamada, Vinciane Rebours, Kazuichi Okazaki, Lingli Dong, Mollie Carruthers, Luke Y.C. Chen, Luca Frulloni, Alireza Meysami, Hiroki Takahashi, Mitsuhiro Kawano, Yanying Liu, Takako Saeki, Mikael Ebbo, Tobias Alexander, Andrés González García, Omer Karadag, Maria Maślińska, Shauna M. Quinn, Allen Poma, Audrey Wells, Thomas J. Greene, John H. Stone, Emma L. Culver, the INDIGO Trial Investigators* 2026-06-02 Obexelimab for the Treatment of IgG4-Related Disease Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. https://www.nejm.org/doi/full/10.1056/NEJMoa2605555?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2605555 Eileen M. O’Reilly, Zev A. Wainberg, Andrew E. Hendifar, Mitesh J. Borad, Filippo Pietrantonio, Shubham Pant, Pascal Hammel, Chiara Cremolini, Gulam A. Manji, Paul E. Oberstein, Ignacio Garrido-Laguna, Christoph Springfeld, Nilofer S. Azad, Makoto Ueno, Stephen Y. Chui, Ying Zhang, Hina Patel, Yeonju Lee, Zeena Salman, Brian M. Wolpin, the RASolute 302 Trial Investigators* 2026-05-31 Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer In HER2-positive gastroesophageal adenocarcinoma, progression-free survival was longer with zanidatamab plus chemotherapy, both with and without tislelizumab, than with trastuzumab plus chemotherapy. https://www.nejm.org/doi/full/10.1056/NEJMoa2517729?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2517729 Kohei Shitara, Elena Elimova, Tianshu Liu, Josep Tabernero, Keun-Wook Lee, Michael Schenker, Niall C. Tebbutt, Jaffer Ajani, Norhidayu Salimin, Geoffrey Ku, Jong Gwang Kim, Inmaculada Ales Diaz, Jingdong Zhang, Filippo Pietrantonio, Li-Yuan Bai, Samuel Le Sourd, Jun Zhao, Cinta Hierro, Andrew Kiberu, Filip Van Herpe, Yuanyuan Bao, Hanze Zhang, Lin Yang, Vincent Li, Elaina M. Gartner, Ye Chen, Jonathan Grim, Sun Young Rha, Lin Shen, the HERIZON-GEA-01 Investigators* 2026-05-28 Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer In two phase 3 trials, 19% of patients with chronic hepatitis B infection had a functional cure with the antisense oligonucleotide bepirovirsen, 24 weeks after stopping all HBV treatment; functional cure was not seen with placebo. https://www.nejm.org/doi/full/10.1056/NEJMoa2515131?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2515131 Jinlin Hou, Seng-Gee Lim, Maria Buti, Man-Fung Yuen, Edward Gane, Pietro Lampertico, Norah Terrault, Huy Nguyen, Hyung Joon Yim, Qing Xie, Jianmei Lin, Yunqing Qiu, Wen-Juei Jeng, Jeong Heo, Cheng-Yuan Peng, Chien-Hung Chen, Wan-Long Chuang, Yao Xie, Maria Hlebowicz, Nevin Idriz, Rajiv Mehta, Kosh Agarwal, Monica M. Gomes da Silva, Alex Franca, Roxana Cernat, Apinya Leerapun, Carla S. Coffin, Adrian Gadano, Pietro Andreone, Shigetoshi Fujiyama, Vasileios Sevastianos, Yuichiro Suzuki, Vlad Ratziu, Ghassan Riachi, Hartmut Stocker, Tien Huey Lim, Tarik Asselah, Yasuhito Tanaka, Jacinta Holmes, Xieer Liang, Jennifer Cremer, Tamara Lukić, Helene Plein, Geoff Quinn, Yu Tao, Melanie Paff, Dickens Theodore, Robert Elston, the B-Well Study Group* 2026-05-28 Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection The new Dietary Guidelines for Americans represent progress in some areas but raise concerns about transparency, internal consistency, practical implementation, and ignoring of key scientific evidence. https://www.nejm.org/doi/full/10.1056/NEJMp2600579?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMp2600579 Deirdre K. Tobias, Frank B. Hu 2026-05-28 The 2025–2030 Dietary Guidelines for Americans — Progress, Pitfalls, and the Path Forward The current treatment of chronic hepatitis B infection includes nucleoside or nucleotide analogue (NA) therapy and pegylated interferon. Both of these treatments are effective in suppressing hepatitis B virus (HBV) replication and in reducing the risk of cirrhosis and hepatocellular carcinoma.1 However, these treatments do not eradicate HBV,... https://www.nejm.org/doi/full/10.1056/NEJMe2605575?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2605575 Anna S. Lok 2026-05-28 A Major Step toward a Cure for Hepatitis B Infection A 51-year-old man presented with a 2-hour history of coffee-ground emesis and difficulty swallowing. Upper endoscopy showed black discoloration and friability of the mucosa from the midesophagus to the gastroesophageal junction. https://www.nejm.org/doi/full/10.1056/NEJMicm2600976?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMicm2600976 Kai Nie, Xiaoyan Wang 2026-05-28 Acute Esophageal Necrosis In a phase 1–2 study of daraxonrasib, treatment-related adverse events of grade 3 or higher occurred in 30% of patients with previously treated RAS-mutated pancreatic cancer, and up to 35% of patients had an objective response. https://www.nejm.org/doi/full/10.1056/NEJMoa2505783?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2505783 Brian M. Wolpin, Wungki Park, Ignacio Garrido-Laguna, Alexander Spira, Alexander Starodub, David Sommerhalder, Salman R. Punekar, Minal Barve, Meredith Pelster, Benjamin Herzberg, Nilofer S. Azad, Joel Randolph Hecht, Sai Hong Ignatius Ou, Tong Lin, Sumit Kar, Lin Tao, Rashmi Vora, Aparna Hegde, Kyaw Aung, David S. Hong, the RMC-6236-001 Investigators† 2026-05-07 Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer The authors describe the scientific foundations of a phase 1–2 study of daraxonrasib to treat metastatic pancreatic ductal adenocarcinomas. https://www.nejm.org/doi/full/10.1056/NEJMe2600517?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2600517 Channing J. Der, Jen Jen Yeh 2026-05-07 Science behind the Study: Advances in RAS Therapeutics for Pancreatic Cancer This article summarizes the pathogenesis, diagnosis, and management of Barrett’s esophagus, a reflux-related condition with increased adenocarcinoma risk, highlighting endoscopic diagnosis, surveillance, and early curative therapy. https://www.nejm.org/doi/full/10.1056/NEJMcp2506887?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMcp2506887 Rebecca C. Fitzgerald 2026-04-30 Barrett’s Esophagus An 86-year-old woman with a history of diabetes and breast cancer was admitted to the hospital with anorexia and weight loss. Imaging revealed multifocal liver lesions. A diagnosis was made. https://www.nejm.org/doi/full/10.1056/NEJMcpc2412525?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMcpc2412525 Margaret M. Chapman, Rory L. Cochran, Kumar Krishnan, Kristen M. Hysell, Ahmad Alkashash 2026-04-23 Case 12-2026: An 86-Year-Old Woman with Anorexia, Weight Loss, and Liver Lesions In a phase 1 trial of setidegrasib, a KRAS G12D degrader, 42% of patients had adverse events of grade 3 or higher; 36% of patients with NSCLC and 24% of those with pancreatic cancer had a response. https://www.nejm.org/doi/full/10.1056/NEJMoa2600752?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2600752 Wungki Park, Anup Kasi, Alexander I. Spira, Luis Paz-Ares Rodríguez, Benjamin O. Herzberg, Meredith S. Pelster, Anthony W. Tolcher, Yasutoshi Kuboki, Shigehisa Kitano, Hirokazu Shoji, Judy S. Wang, Jordan D. Berlin, Antoine Hollebecque, Patricia LoRusso, Christos Fountzilas, Philippe A. Cassier, Tomohiro Nishina, Daisuke Sakai, Chiaki Inagaki, Daniel Morgensztern, Makoto Ueno, Minkyu Jung, Sang-We Kim, Pasi A. Jänne, Antoine Italiano, Benoît You, T Macarulla, Hisaki Fujii, Aditya Shetty, Ying Lu, Daniel Cui, Shilpa Kadam, Stanley C. Gill, Junko Toyoshima, Takeshi Saito, Jonathan W. Goldman 2026-04-09 Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer This review summarizes the epidemiology, diagnosis, and management of celiac disease and highlights serologic testing, biopsy confirmation, associated autoimmune conditions, and a gluten-free diet as treatment. https://www.nejm.org/doi/full/10.1056/NEJMcp2415548?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMcp2415548 Joseph A. Murray, Steffen Husby 2026-04-09 Celiac Disease